



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/997,440	11/15/2001	David Botstein	P2730P1C31	3276
7590	07/08/2008		EXAMINER	
GINGER R. DREGER			WEGERT, SANDRA L	
HELLER EHRLICH WHITE & MCAULIFFE LLP				
275 MIDDLEFIELD ROAD			ART UNIT	PAPER NUMBER
MENLO PARK, CA 94025			1647	
			MAIL DATE	DELIVERY MODE
			07/08/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	09/997,440	BOTSTEIN ET AL.
	Examiner	Art Unit
	SANDRA WEGERT	1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 17 March 2008.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 119-126 and 129-131 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 119-126 and 129-131 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on 15 November 2001 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ . |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____. | 6) <input type="checkbox"/> Other: _____ . |

Detailed Action

Status of Application, Amendments, and/or Claims

The Arguments, submitted 17 March 2008, has been entered. Claims 1-118, 127 and 128 were cancelled previously by Applicants.

Claims 119-126 and 129-131 are under examination in the Instant Application.

Maintained Objections and/or Rejections

Claim Rejections-35 U.S.C. § 101/112, first paragraph-, Lack of Utility, Enablement.

The following is a quotation of 35 U.S.C. 101:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 119-126 and 129-131 are rejected under 35 U.S.C. 101, as lacking utility. The reasons for this rejection under 35 U.S.C. § 101 are set forth at pp. 2-8 of the previous Office Action (16 October 2007). Claims 119-126 and 129-131 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific

and substantial asserted utility or a well established utility for the reasons set forth in the previous Office Action (16 October 2007), one skilled in the art clearly would not know how to use the claimed invention.

A portion of the basis for these rejections is withdrawn. Specifically, the examiner no longer asserts that mRNA levels are not predictive of polypeptide levels. Therefore, the following references are no longer being relied upon to support the rejections: Haynes et al., Pennica, et al, Konopka, et al, (of record in the instant application), Godbout, et al (1998, J. Biol. Chem, 273(33): 211610-21168, of record in the parent application), and Li et al., (2006, Oncogene, Vol. 25, pages 2628-2635, of record in the parent application). Therefore, Applicants' arguments concerning those references will no longer be addressed (Remarks/Arguments, 17 March 2008, pages 8-11). The basis of the maintained rejections is solely that **gene amplification** levels are not predictive of mRNA or polypeptide levels, and that the gene amplification data presented is not a reliable indicator of disease.

At pages 539-555 of the specification, Table 9 and Example 170 show the results of a gene amplification assay in which genomic DNA encoding PRO1153 had a ΔCt value of at least 1.0 for approximately 6% of two types of lung tumors when compared to a pooled control of blood DNA from several healthy volunteers. Example 170 asserts that gene amplification is associated with overexpression of the gene product (i.e., the polypeptide), indicating that the polypeptides are useful targets for therapeutic intervention in cancer and diagnostic determination of the presence of cancer (p. 555, first paragraph). At page 548, ΔCt is defined as the threshold PCR cycle, or the cycle at which the reporter signal accumulates above the background level of fluorescence. The specification further indicates that ΔCt is used as "a

quantitative measurement of the relative number of starting copies of a particular target sequence in a nucleic acid sample when comparing cancer DNA results to normal human DNA results.” It is noted that at page 548 it is stated that samples are used if their values are within 1 Ct of the normal DNA standard. It is further noted that the ΔCt values in Table 9 are expressed (a) with values to one one-hundredth of a unit (e.g. 1.36).

First, there are several problems with the data provided in this example. The art recognizes that lung cells can be aneuploid without the presence of cancer. Specifically, Hittelman (2001, Ann. N. Y. Acad. Sci. 952:1-12) reports that lung epithelium is at risk for cellular damage due to direct exposure to environmental pollutants and carcinogens, which result in aneuploidy **before** the epithelial cells turn cancerous. See especially p. 4, Figure 4. The gene amplification assay in the instant specification does not provide a comparison between the lung tumor samples and normal lung epithelium and does not correct for aneuploidy. Thus it is not clear that PRO1153 is amplified in cancerous lung epithelium more than in damaged (non-cancerous) lung epithelium. One skilled in the art would not conclude that PRO1153 is a diagnostic probe for lung cancer unless it is clear that PRO1153 is amplified to a clearly greater extent in true lung tumor tissue relative to non-cancerous lung epithelium.

Second, even if the data had been corrected for aneuploidy and a proper control had been used, the data have no bearing on the utility of the claimed PRO1153 peptide produced by the disclosed gene. In order for PRO1153 polypeptide to be overexpressed in tumors, amplified genomic DNA would have to correlate with increased mRNA levels and increased polypeptide levels. No data regarding PRO1153 mRNA or PRO1153 polypeptide levels in lung or colon tumors have been brought forth on the record. The art discloses that a correlation between

genomic DNA levels and mRNA levels cannot be presumed, nor can any correlation between genomic DNA levels and polypeptide levels.

Applicants argue (Remarks/Arguments, 17 March 2008, page 3, for example) that the results presented in the instant Specification are enabling for the polypeptide of SEQ ID NO: 351. They argue that the PRO1153 nucleic acid is a diagnostic marker for lung adenocarcinomas and squamous cell carcinoma of the lung, and point to the results of the amplification assay. The assay indicated (Table 9, Specification) showed a 2-fold or greater fluorescence in some samples of lung adenocarcinoma (LT4), but not others (LT1 through LT3, among others).

Applicant's arguments (17 March 2008) have been fully considered but are not found to be persuasive for the following reasons:

In the instant case, the specification provides data showing an increase in DNA copy number- about 2 fold or greater- in some lung tumors, but not others. The literature cautions researchers against drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue. For example, Hu et al. (2003, Journal of Proteome Research 2: 405-412, of record) analyzed 2286 genes that showed a greater than 1-fold difference in mean expression level between breast cancer samples and normal samples in a microarray (p. 408, middle of right column). Hu et al. discovered that, for genes displaying a 5-fold change or less in tumors compared to normal, there was no evidence of a correlation between altered gene expression and a known role in the disease. However, among genes with a 10-fold or more change in expression level, there was a strong and significant correlation between expression level and a published role in the disease (see discussion section).

The specification of the instant application does not complement the low (2-fold) PRO1153 gene expression data with any other data that indicates a role in disease. The asserted utility for the claimed polypeptide is based on the assumption that the PRO1153 gene plays a role in disease or is a marker for disease. However, the instant disclosure does not show reliable fluorescence of PRO1153 even within the same experimental group. In addition, the instant Specification does not provide proper statistical analysis such as reproducibility, standard error rates, etc. When viewed with the evidence of record as a whole, there is no correlation between gene amplification and a role of PRO1153 in disease. In view of the totality of the evidence, including the declarations submitted under 37 CFR 1.132 and the publications of record, the instant utility rejection is appropriate.

Applicants assert that the Patent Office has failed to meet its initial burden of proof that claims of Utility are not substantial or credible. They contend that the examiner's reasoning is based on a misrepresentation of the scientific data presented in the cited references and application of an improper, heightened legal standard. Applicants state that whether the PRO gene is amplified in few tumor samples or in the vast number of tumor samples is not relevant to its utility as a tumor marker (17 March 2008, page 5).

Applicant's arguments have been fully considered but are not found to be persuasive. The truth or credibility of the assertion of utility has not been questioned. Rather, the rejection sets forth that the assertion of utility is not substantial. The preponderance of evidence, taken into consideration with the disclosure, indicate to the skilled artisan that it is more likely than not that PRO1153 gene, polypeptide and antibody are not useful as cancer diagnostic agents.

Applicants indicate that the PRO1153 nucleic acid was amplified in a significant number of lung tumors and showed a large increase in gene copy number, i.e., at least 2-fold amplification. At pages 4 and 5 of the Response, Applicants argue that the amplification of the nucleic acid encoding the claimed polypeptide is significant for the detection of lung cancer and cite the Declarations under 37 CFR § 1.132. However, no substantially new arguments have been presented. Except for the Goddard declaration, these declarations were previously considered and discussed by the Examiner in the Office Action of 18 October 2004. However, it is again noted that the PRO1153 gene has *not* been associated with tumor formation or the development of cancer, nor has it been shown to be predictive of such. The specification merely demonstrates that the PRO1153 nucleic acid was amplified in about 6% of the cancer samples studied. No mutation or translocation of PRO1153 has been associated with any type of cancer. In addition, the data were not corrected for aneuploidy, a phenomenon that occurs in cancerous and non-cancerous lung. For these reasons, it is not clear that the reported amplification is meaningful. In the absence of any of the above information, all that the specification has done is present evidence that the DNA encoding PRO1153 is amplified in some cancer samples and invites the artisan to determine the significance of this increase. One cannot determine from the data in the specification whether the observed “amplification” of nucleic acid is due to increase in chromosomal copy number, or alternatively due to an increase in transcription rates. It remains that the issue is simply not predictable, and the specification presents a mere invitation to experiment.

Similarly, Applicants argue (Response, 17 March 2008, page 5) that even if a *prima facie* case of lack of utility has been established, it should be withdrawn on consideration of the

totality of the evidence. Applicants provide evidence in the form of a publication by Hanna & Mornin (of record). Applicants contend that the publication teaches that the HER-2/neu gene is over-expressed in breast cancers, and teaches that diagnosis of breast cancer includes testing both the amplification of the HER-2/neu gene as well as over-expression of the HER-2/neu gene product. Applicants also argue that the disclosed assay leads to a more accurate classification of the cancer and a more effective treatment of it. The examiner agrees. In fact, Hanna & Mornin supports the instant rejection, in that the authors show that gene amplification does not reliably correlate with polypeptide over-expression; thus, the level of polypeptide expression must be tested empirically. The instant specification does not provide this additional information, and therefore the skilled artisan would need to perform additional experiments. Since the asserted utility for the claimed polypeptides is not in currently available form, the asserted utility is not substantial.

Therefore, based on the totality of the evidence, it is maintained that one skilled in the art would view the instant gene amplification data as merely preliminary with regard to whether PRO1153 plays a role in disease or can be used as a marker of disease in the types of lung tumors tested. Therefore, since the claimed invention does not provide products or services in “currently available form” to the public, the asserted utility is not substantial.

The fact remains that the instant specification does not disclose whether or not the PRO1153 gene is *reliably* overexpressed in any tumor tissues. Only about 6% of the experimental samples tested positive, even within each tumor type and subtype. For these reasons the skilled artisan must perform further research in order to reasonably confirm overexpression and specificity of positive fluorescence. The requirement for such further

research indicates that the asserted utility of PRO1153 as a cancer diagnostic agent is not substantial. Furthermore, the specification does not disclose the expression levels of PRO1153 protein in any tumor samples, such that one can be sure that the claimed peptide can be used as a tumor marker; such would have to be determined through further research on the part of the skilled artisan. Thus, even the utility proposed regarding the usefulness of the PRO1153 peptide in the diagnosis of cancer is not substantial. Finally, there is no disclosure regarding what treatment modality should be chosen by the clinician based on whether or not the PRO1153 gene is overexpressed. The determination of such constitutes further experimentation, indicating that the asserted utility is not substantial. Finally, since the disclosed PRO1153 gene and claimed protein lack utility, there would be no reason to raise antibodies to detect them.

Applicants conclude that one of skill in the art would reasonably expect in this instance, based on the amplification data for the PRO1153 gene, that the PRO1153 polypeptide has utility in the diagnosis of cancer, and, based on such a utility, one of skill in the art would know exactly how to use the claimed polypeptide for diagnosis of cancer.

Applicant's arguments have been fully considered but are not found to be persuasive. The Examiner concedes that the specification teaches how to make the PRO1153 polypeptide as well as antibodies that bind the polypeptide. However, the specification fails to provide a substantial asserted utility for the PRO1153 gene, and thus the specification also fails to enable the PRO1153 polypeptides and antibodies (specifically, the specification fails to teach the skilled artisan how to use the claimed PRO1153 polypeptides and antibodies without undue experimentation). As discussed above, PRO1153 genomic DNA was found to be slightly amplified in only a few types and subtypes of lung cancer samples compared to a normal DNA

control. The data were not corrected for aneuploidy, which was known to be common in cancerous *and non-cancerous* lung tissue. Thus, it is not clear from the gene amplification data whether or not PRO1153 genomic DNA actually is amplified in certain lung tumors. In view of the totality of the evidence, the skilled artisan would not reasonably assume that PRO1153 is reliably overexpressed in certain lung tumors based on the disclosure regarding gene amplification, *without further experimentation*. The requirement for such testing indicates that the asserted utility is not substantial, i.e., it is not in currently available form. In view of such and the lack of guidance regarding how a physician might use information regarding PRO1153 overexpression, or lack of overexpression, in categorizing a tumor and choosing a treatment modality, the asserted utility for PRO1153 as a cancer diagnostic agent is not substantial. In view of the totality of the evidence, the rejections for lack of utility and enablement are proper.

35 USC § 112, first paragraph – Written Description.

Claims 119-123 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention. The reasons for this rejection under 35 U.S.C. § 112, first paragraph, are set forth at pp. 8-12 of the previous Office Action (16 March 2007). Briefly, the Applicants were not in possession of all or a significant number of polypeptides that have 80-99% homology to SEQ ID NO: 351 and still retain the function of SEQ ID NO: 351.

Applicants did not discuss the Written Description rejection except to maintain that "Claims 119-123 satisfy the written description requirement" (Remarks, 17 March 2008, p. 12).

As argued in previous Office Actions (such as that of 25 March 2004 and all subsequent Actions), applicants have not described or shown possession of all polynucleotides 80-99% homologous to SEQ ID NO: 351, which still retain the function of SEQ ID NO: 351. Nor have Applicants described a representative number of species that have 80-99% homology to SEQ ID NO: 351, such that it is clear that they were in possession of a genus of polypeptides functionally similar to SEQ ID NO: 351. Applicants have made no variant polypeptides, and as recited in the current Written Description Guidelines, Applicants must have invented the subject matter that is claimed and must be in "possession" of the claimed genus (Federal Register, 2001, Vol. 66, No. 4, pages 1099-1111, esp. page 1104, 3rd column).

Conclusion

No claims are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Advisory information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (571) 272-0895. The examiner can normally be reached Monday - Friday from 9:00 AM to 5:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Manjunath Rao, can be reached at (571) 272-0939.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (in USA or CANADA) or 571-272-1000.

/SLW/
30 June 2008

/Elizabeth C. Kemmerer/
Primary Examiner, Art Unit 1646